Protagenic Therapeutics (PTIX) & Its Peers Financial Comparison

Protagenic Therapeutics (NASDAQ:PTIX) is one of 968 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it contrast to its competitors? We will compare Protagenic Therapeutics to similar businesses based on the strength of its earnings, valuation, dividends, risk, institutional ownership, profitability and analyst recommendations.

Profitability

This table compares Protagenic Therapeutics and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Protagenic Therapeutics	N/A	-101.81%	-82.18%
Protagenic Therapeutics Competitors	-2,638.22%	-226.71%	-28.57%

Valuation & Earnings

This table compares Protagenic Therapeutics and its competitors gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Protagenic Therapeutics	N/A	-$5.00 million	-1.12
Protagenic Therapeutics Competitors	$1.59 billion	$140.37 million	-4.49

Protagenic Therapeutics’ competitors have higher revenue and earnings than Protagenic Therapeutics. Protagenic Therapeutics is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Insider and Institutional Ownership

8.0% of Protagenic Therapeutics shares are owned by institutional investors. Comparatively, 44.6% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 37.0% of Protagenic Therapeutics shares are owned by insiders. Comparatively, 14.5% of shares of all “Pharmaceutical preparations” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Risk and Volatility

Protagenic Therapeutics has a beta of 0.36, meaning that its share price is 64% less volatile than the S&P 500. Comparatively, Protagenic Therapeutics’ competitors have a beta of 0.84, meaning that their average share price is 16% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings for Protagenic Therapeutics and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protagenic Therapeutics	0	0	0	0	N/A
Protagenic Therapeutics Competitors	5936	17803	43170	880	2.58

As a group, “Pharmaceutical preparations” companies have a potential upside of 86.62%. Given Protagenic Therapeutics’ competitors higher probable upside, analysts clearly believe Protagenic Therapeutics has less favorable growth aspects than its competitors.

Summary

Protagenic Therapeutics competitors beat Protagenic Therapeutics on 6 of the 10 factors compared.

About Protagenic Therapeutics

Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. The company's lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York.